Research ReportsPiramal Pharma - Geared To Drive Robust Operating Leverage Across Segments: Motilal Oswal
ADVERTISEMENT
Piramal Pharma - Geared To Drive Robust Operating Leverage Across Segments: Motilal Oswal
The brokerage maintains its Buy rating on the stock with a target price of Rs 260, based on SOTP (17x EV/Ebitda for CDMO business; 13x EV/Ebitda for CHG, India consumer health business).
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.